Search

Your search keyword '"van Andel G"' showing total 163 results

Search Constraints

Start Over You searched for: Author "van Andel G" Remove constraint Author: "van Andel G"
163 results on '"van Andel G"'

Search Results

1. Uitkomsten in de dagelijkse praktijk van eerstelijnschemotherapie voor niet-resectabel stadium III en IV urotheelcarcinoom van de blaas.

2. Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study

Catalog

Books, media, physical & digital resources

3. The membranous urethral length: A continence predictor on MRI with high interobserver variability

4. Corrigendum to 'Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study' (Urologic Oncology: Seminars and Original Investigations (2020) 38(9) (735.e17–735.e25), (S1078143920302519), (10.1016/j.urolonc.2020.05.022))

5. Evaluating machine learning algorithms to Predict 30-day Unplanned REadmission (PURE) in Urology patients.

6. Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.

7. Complications of transperineal prostate biopsies with antibiotic prophylaxis on indication only versus transrectal prostate biopsies with standard prophylactic antibiotics

11. The effect on quality of life of androgen deprivation therapy (ADT) combined with local external prostate radiotherapy in patients with primary metastatic prostate cancer, results from the HORRAD trial

21. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

22. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

29. Duration of androgen suppression in the treatment of prostate cancer

31. 997 EORTC nomograms for predicting recurrence, progression, overall and disease specific survival in non-muscle invasive Ta T1 bladder cancer patients treated with maintenance Bacillus Calmette-Guerin

33. Meer inzicht in praktijkvoering: Diagnose-behandel-combinaties ondersteunen medisch specialisten

35. 1050 Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer

36. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group

46. Health-related quality of life in Dutch men with prostate cancer.

47. Changes in health-related quality of life of men with prostate cancer 3 months after diagnosis: the role of psychosocial factors and comparisment with benign prostate hyperplasia patients.

48. Psychosocial and educational aspects in prostate cancer patients.

49. Quality of Life Assessment in Patients with Hormone–Resistant Prostate Cancer Treated with Epirubicin or with Epirubicin plus Medroxy Progesterone Acetate – Is It Feasible?

50. Arterial occlusion following angiography